Contineum Therapeutics (CTNM) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.49
- Estimate
- -$0.45
- Surprise
- -8.2%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Contineum Therapeutics (CTNM) reported a wider loss than forecast — adjusted EPS of -$0.49 against the -$0.45 estimate (a 8.2% shortfall).
Coverage in the report window
- Contineum Therapeutics, Inc. 12-Month Price Target Adjusted to $21.43 — fiscal.ai, 2026-11-05
- Contineum Therapeutics Reports Third-Quarter 2026 Financial Results — fiscal.ai, 2026-11-03
- Contineum Says Phase 2 PROPEL-IPF Trial Has Over 100 Sites Online In 16 Countries; Cash Runway Through Mid-2029 — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates CTNM Hold at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -8.2% surprise compares with a +0.8% four-quarter average. Next scheduled report: 2027-03-04.
What argues against it
- Concentration risk — Pipeline: PIPE-791
- Market cap $363M below $400M minimum
- Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -5577.0%), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.04
- Price target
- $18.64
- Stop
- $8.41
- Upside to target
- +106.2%
- Reward-to-risk
- 7.1:1
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
CTNM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $362.8M
- P/E (fwd)
- -4.4
- 52-week range
- $6.72–$17.79
- Off 52-week high
- 49.2%
- RSI (14)
- 47
- Volume vs avg
- 0.49×
- Score today
- 5.2/10